drugset / Trial / NCT00985998
Nimotuzumab in Combination With Cisplatin and Docetaxel for Patients With Advanced Non-small Cell Lung Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Nimotuzumab (hR3) is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR). Clinical efficacy has been shown in adult with head and neck cancer. The study assessed the safety, and efficacy of the combination of Nimotuzumab administered concomitantly with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).
Timeline
- Start
- 2009-09
- Primary completion
- 2015-08
- Completion
- 2015-08
Outcome
Outcome not reported
Stopped (Enrollment): “no paticipants enrolled”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nimotuzumab | Monoclonal antibody | 200 mg | — |
| Subject | Nimotuzumab | Monoclonal antibody | 400 mg | — |
| Subject | Nimotuzumab | Monoclonal antibody | 600 mg | — |
| Background | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Background | Docetaxel | Small molecule | 75 mg/m2 | — |